Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: SC-III3, a novel scopoletin derivative, induces cytotoxicity in hepatocellular cancer cells through oxidative DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation

Figure 2

SC-III3 inhibited cell growth of HepG2 cells. (A) HepG2 cells were treated with SC-III3 for 24 and 48 h, and cell viability was analyzed by MTT assay. (B) LO2 cells were treated with SC-III3 for 24 and 48 h. (C) HepG2 cells were treated with doxorubicin (DOX) for 24 and 48 h. (D) LO2 cells were treated with DOX for 24 and 48 h. Data were presented as means ± SEM of three separate experiments. The difference were significant at *p < 0.05, **p < 0.01 vs. control.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us